Vir Biotechnology (VIR) Income towards Parent Company (2018 - 2026)

Vir Biotechnology has reported Income towards Parent Company for 9 years, with the latest figure at -$125.7 million in Q1 2026.

• Quarterly Income towards Parent Company fell 3.91% year-over-year to -$125.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$442.7 million (up 23.36% YoY) and the FY2025 annual result came in at -$438.0 million, up 16.09% from the prior year.
• Income towards Parent Company eased to -$125.7 million in Q1 2026 per VIR's latest filing, from -$42.9 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $518.6 million in Q1 2022 and troughed at -$213.7 million in Q3 2024.
• A 5-year average of -$69.7 million and a median of -$116.0 million in 2023 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 407.04% in 2022, down 223.75% in 2022.
• Over 5 years, Income towards Parent Company stood at -$101.6 million in 2022, then dropped by 14.14% to -$116.0 million in 2023, then grew by 9.82% to -$104.6 million in 2024, then surged by 58.96% to -$42.9 million in 2025, then tumbled by 192.84% to -$125.7 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$125.7 million, -$42.9 million, and -$163.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.